Germany's Fresenius raises 2024 forecast after Q3 beat
Adds details and CEO quote from paragraph 4
Nov 6 (Reuters) -Germany's Fresenius FREG.DE raised its full-year outlook on Wednesday after beating third-quarter expectations, citing strong performances at its Kabi and Helios divisions.
The healthcare group said it expects organic revenue growth of 6%-8%, from a previously anticipated 4%-7%.
It also raised its forecast of constant currency earnings before interests and taxes (EBIT) before special items growth to 8%-11% from 6-10%.
Fresenius reported third-quarter revenue of 5.30 billion euros ($5.69 billion) and EBIT before special items of 522 million euros, beating a company-provided consensus by 1.7% and 3.4% respectively.
"Both Kabi and Helios continue to deliver consistent and sustained financial performance," CEO Michael Sen said in a statement.
Since taking the helm in October 2022, Sen has been revamping the organization to reduce expenditures and liabilities following a drop in profits at its previous dialysis unit, Fresenius Medical Care FMEG.DE.
This restructuring initiative has prioritized Fresenius Kabi, a producer of generic hospital medications, and Helios, which operates a network of hospitals in Germany and Spain.
($1 = 0.9315 euros)
Reporting by Tristan Veyet and Rafal W. Nowak in Gdansk; Editing by Varun H K
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
